Evotec's Restructuring Plan Shows Early Promise Amid Cautious Outlook

Evotec's cost cuts exceed targets, but a conservative 2026 forecast creates uncertainty ahead of tomorrow's full-year results and strategic webcast.

Investors are awaiting Evotec SE's full-year 2025 results tomorrow, with expectations tempered by the company's own conservative guidance for the following year. While the "Horizon" restructuring initiative is delivering savings ahead of schedule, a disappointing 2026 forecast has created uncertainty.

Exceeding Savings Targets

Preliminary figures present a mixed financial picture. Revenue saw a modest decline to €788 million from €797 million. However, the company's adjusted operating profit showed significant improvement, rising to €41 million from €22.5 million. The Horizon cost-cutting program is progressing better than anticipated, with projected savings for 2025 now exceeding €60 million—double the initial target. This has been achieved through the elimination of approximately 280 positions and a planned reduction in operational sites from 19 to 10.

The central question for the market is whether these measures justify the outlook for 2026. Evotec's EBITDA target range of €0 to €40 million falls substantially below analyst consensus estimates of over €80 million. Concurrently, management anticipates revenue to drop to between €700 million and €780 million. Tomorrow's report and webcast will be scrutinized for evidence that this cautious planning is grounded in operational reality rather than being merely a buffer against potential further headwinds.

Operational Highlights and Strategic Moves

Beyond the financial forecasts, Evotec has recently announced several concrete developments. A Phase 1 clinical trial for the CELMoD drug candidate BMS-986506, conducted by partner Bristol Myers Squibb, has triggered a $10 million milestone payment. Furthermore, the divestment of its biologics site in Toulouse to Sandoz generated approximately $350 million in immediate cash, with the potential for over $300 million in additional future license and milestone fees. In a notable vote of confidence, Goldman Sachs has more than doubled its stake in Evotec to 6.12%.

The company's medium-term ambition, targeting an 8% to 12% compound annual growth rate in revenue and adjusted EBITDA margins above 20% by 2028, remains intact. The clarity of the path toward these goals, to be outlined in Wednesday's webcast at 14:00 MESZ, is likely to be the primary driver of the stock's reaction to the earnings release. The Annual General Meeting is scheduled for June 11, 2026.